AI Scribe for Oncologists
Document chemotherapy visits, tumor assessments, and treatment plans in seconds. PatientNotes captures RECIST criteria, CTCAE toxicity grading, and generates comprehensive oncology documentation.
Documentation for Every Oncology Visit
From diagnosis through survivorship, PatientNotes handles all oncology documentation needs
Chemotherapy Visits
Complete infusion documentation with dose calculations, pre-meds, vital signs, and toxicity grading.
New Cancer Diagnosis
Initial consultation, staging workup, treatment planning, and patient education documentation.
Tumor Assessments
RECIST measurements, response evaluation, and imaging review with progression determination.
Radiation Planning
Simulation, contouring, dose prescriptions, and on-treatment visits with toxicity monitoring.
Survivorship Care
Long-term follow-up, surveillance protocols, late effects monitoring, and wellness counseling.
Supportive Care
Pain management, nausea control, neutropenic fever, and symptom-directed interventions.
Oncology-Specific Features
Built for the unique documentation needs of oncology
Treatment Protocol Documentation
Automatic capture of regimen names, cycle numbers, dose modifications, and reason for changes. Links to NCCN guidelines.
CTCAE Toxicity Grading
Structured adverse event documentation using Common Terminology Criteria with automatic grade assignment and dose adjustment recommendations.
RECIST Response Assessment
Track target lesions, calculate sum of diameters, compare to baseline, and automatically determine response category.
Performance Status Tracking
ECOG and Karnofsky scores with trend analysis over treatment course. Flags for declining performance requiring intervention.
Molecular Marker Integration
Document biomarkers, genomic testing, PDL1 expression, MSI status, and targeted therapy eligibility.
Tumor Board Templates
Structured multidisciplinary notes with pathology, staging, imaging, and team recommendations.
Sample AI-Generated Oncology Note
See how PatientNotes documents a chemotherapy visit with response assessment
SUBJECTIVE: 62-year-old female with stage IV non-small cell lung cancer (adenocarcinoma, EGFR wild-type, PDL1 80%) presents for cycle 3, day 1 of pembrolizumab and carboplatin/pemetrexed. Tolerating treatment well overall. Reports mild fatigue (improved from last week) and intermittent dry cough. No fever, shortness of breath, or chest pain. Good appetite, weight stable. ECOG PS 1. Current symptoms: - Fatigue: Grade 1 (CTCAE), manageable with rest - Cough: Intermittent, dry, no hemoptysis - No neuropathy, rash, diarrhea, or other new symptoms OBJECTIVE: Vitals: BP 128/76, HR 72, Temp 98.2°F, RR 16, O2 sat 96% on RA, Weight 62.3 kg Performance Status: ECOG 1 Physical Exam: General: Well-appearing, no acute distress HEENT: No oral lesions, moist mucous membranes Cardiovascular: Regular rate and rhythm, no murmurs Pulmonary: Clear to auscultation bilaterally, no wheezes or rales Abdomen: Soft, non-tender, no hepatosplenomegaly Extremities: No edema, no rash Neuro: Alert and oriented, no focal deficits Recent Labs (today): CBC: WBC 6.2, Hgb 11.8, Plt 220, ANC 3.8 CMP: Cr 0.9, eGFR >60, AST 28, ALT 32, Bili 0.6 Imaging Review (CT chest/abdomen/pelvis from 2 weeks ago): Target Lesions: - Right upper lobe mass: 3.2 cm (baseline 4.8 cm) - 33% decrease - Right hilar lymph node: 1.8 cm (baseline 2.4 cm) - 25% decrease Sum of diameters: 5.0 cm (baseline 7.2 cm) - 31% decrease from baseline Non-target lesions: Small pleural nodules stable New lesions: None Assessment: Partial Response (RECIST 1.1) ASSESSMENT: 1. Stage IV NSCLC (T3N2M1b) - showing excellent partial response to pembrolizumab/carboplatin/pemetrexed 2. Chemotherapy-related fatigue, Grade 1, improving 3. Baseline chronic cough, stable PLAN: 1. Continue pembrolizumab 200mg IV + carboplatin AUC 5 + pemetrexed 500mg/m2 today (cycle 3, day 1) 2. Pre-medications: dexamethasone 8mg IV, ondansetron 16mg IV, famotidine 20mg IV 3. Excellent response to therapy - will complete planned 4 cycles, then continue pembrolizumab maintenance 4. Repeat imaging after cycle 4 5. Continue vitamin B12 and folic acid supplementation 6. Next visit: Day 21 for cycle 4 7. Patient counseled on immunotherapy toxicities - report any rash, diarrhea, or breathing changes immediately 8. Discussed excellent treatment response and prognosis - patient encouraged
Intelligent ICD-10 Suggestions
PatientNotes suggests the codes most commonly used in oncology
C50.919Malignant neoplasm of breast, unspecifiedC34.90Malignant neoplasm of lung, unspecifiedC18.9Malignant neoplasm of colon, unspecifiedC61Malignant neoplasm of prostateC79.51Secondary malignant neoplasm of boneZ51.11Encounter for chemotherapyR50.9Fever, unspecifiedD64.81Anemia due to antineoplastic chemotherapyAI suggests relevant codes based on your documentation—review and select with one click.
Frequently Asked Questions
Can PatientNotes document chemotherapy treatment plans?
Yes. PatientNotes captures complete chemotherapy documentation including regimen details, dose calculations, cycle day, pre-medications, infusion times, and toxicity assessments using CTCAE grading.
Does PatientNotes support tumor response assessment?
Yes. PatientNotes can document RECIST criteria measurements, compare to baseline and prior scans, calculate percentage change, and determine response category (CR, PR, SD, PD).
How does PatientNotes handle tumor board presentations?
PatientNotes has specialized templates for tumor board notes including patient history, pathology, staging, imaging findings, molecular markers, and multidisciplinary recommendations with structured formatting.
Can PatientNotes track performance status and quality of life metrics?
Yes. PatientNotes tracks ECOG and Karnofsky performance status over time, along with symptom burden and PRO-CTCAE patient-reported outcomes, helping identify trends and treatment impacts.
See More Patients, Document Less
Join oncologists saving 2+ hours daily on documentation. PatientNotes handles the charting so you can focus on your patients.
No credit card required. $50/month after trial.